A study. was conducted into the effectiveness of transdermal delivery of hyoscine methobromide using a new system which releases the drug into the circulation at a controlled rate. In six patients whose duodenal ulcer had healed secretion of acid was measured over two nights, the first on placebo and the second on hyoscine methobromide. All patients responded to the active drug and showed a significant inhibition of acid secretion. Four
Introduction
Anticholinergic drugs have been used extensively in the treatment of duodenal ulcers, but less so after' the introduction of derivatives of liquorice and histamine H -receptor antagonists -3 and the renewal of interest in complexed bismuth. 4 Though anticholinergics decrease basal, nocturnal, and stimulated acid output in patients with and without duodenal ulcers,' 5 6 their use is severely limited by side effects of widespread para-sympathetic blockade evoked by the usual therapeutic doses. These effects may be produced by blood concentrations of anticholinergics that exceed the concentrations necessary for gastric secretory inhibition, but they are inescapable if drugs are administered in conventional tablet form. We report on an anticholinergic drug (hyoscine methobromide) given using a new transdermal therapeutic system7 (Transderm V, CIBA Pharmaceutical Company) that delivers the drug into the circulation at a controlled, predetermined rate. This treatment effectively inhibited nocturnal secretion of acid in patients with duodenal ulcer.
Patients and methods
Transdermal therapeutic system is a multilayer laminate 2-5 cm2 in area and 200 pm thick (fig 1) . The system comprises a drug reservoir containing hyoscine methobromide in a polymeric gel, surrounded by an impermeable backing membrane and a microporous membrane, which controls the rate of release. It is fastened to the skin by an adhesive layer, which also acts as a reservoir for a priming dose of hyoscine methobromide. The microporous membrane allows hyoscine methobromide to be released at a constant rate of 4 
Results
Gastric aspirates were technically unsatisfactory in one subject and he was excluded from analysis. In the remaining five patients the mean hourly (2300-0800) acid output decreased from 6- significant (p < 001, figs 2 and 3). All the patients responded to hyoscine methobromide administered via the transdermal therapeutic system (fig 2) . The H+ concentration was unaffected (79-1±6-4 mmol(mEq)/l on placebo, 68 2±3-5 mmol/l on hyoscine methobromide). Four of the subjects reported a dry mouth after overnight hyoscine methobromide and one of them also noticed this shortly after the transdermal therapeutic system was applied to the skin. There were no other side effects.
Discussion
These results suggest that transdermal delivery of hyoscine methobromide at about 5 p.g/h significantly inhibits nocturnal secretion of acid in patients with duodenal ulcer. Others have shown that basal daytime output of acid may also be significantly decreased by transdermal delivery of hyoscine methobromide.8 The transdermal therapeutic system delivers the drug at a steady rate over 72 h. 9 The relapse rate of healed duodenal ulcers may be significantly decreased by the nightly administration of cimetidine 400 mg, which inhibits overnight secretion of acid.10 This system is therefore potentially useful as a maintenance treatment for healed duodenal ulcers, either alone or in combination with a smaller than usual dose of histamine H.-receptor blocking drugs. The ease of a schedule of three-day administration is especially attractive.
Transdermal delivery of hyoscine methobromide effectively prevents the symptoms of natural or experimentally induced motion sickness.11 12 Effects of hyoscine methobromide on daytime acid output-for example, stimulated by meals-are not yet known, but it would seem reasonable to explore its potential in the short-term healing of duodenal ulcers.
Four patients complained of dry mouth. Previous data suggest, however, that in larger numbers of non-intubated subjects the incidence of this side effect is low and transient11-13: wider use will determine whether this side effect is troublesome.
Other observations recorded in this study deserve mention. Firstly, some patientsdonotrespondtoH2-blockade.' Cimetidine had previously failed to inhibit nocturnal secretion of acid in one patient in this study whQse In the past five years it has also been shown that some patients with Sjogren's syndrome develop antibodies to the recently described nuclear antigens SS-A and SS-B.5 The nomenclature has become confused as other groups have identified similar antibodies but given them different names. SS-A seems to correspond to the Ro antigen described by Reichlin2 and SS-B to both the so-called La and Ha antigens.6 Of the two, SS-B has been more closely associated with Sjogren's syndrome.2
Most of the reports linking SS-B antibodies with Sjogren's syndrome have concentrated on patients in whom the diagnosis was well established. We have studied a population who were known to be SS-B positive but whose accompanying diseases were not initially fully known. We were particularly interested to see whether finding antibodies to SS-B might be of predictive value so far as an underlying diagnosis of Sjogren's syndrome was concerned. Sera from patients with rheumatoid arthritis, systemic lupus erythematosus, and polyendocrine syndromes who had no evidence of Sjogren's syndrome were used as controls. In addition to assessing their sera for antibodies to SS-B we also tested for a panel of other autoantibodies.
Patients and methods
In the past two years 55 patients whose sera showed speckled antinuclear antibody (ANA) by indirect immunofluorescence were identified as having SS-B antibodies by counterimmunodiffusion. Fifteen of these patients agreed to undergo examination to see if the antibodies correlated with the presence of Sjogren's syndrome. This was diagnosed on the basis of their having (a) four or more of the symptoms of Sjogren's syndrome described by Anderson et al8; (b) a positive Schirmer's test result (the filter paper strips (Clement Clarke, London) being damped to less than 10 mm after challenge with smelling salts for five minutes); (c) a positive labial biopsy appearance (graded 3 or 4 according to the criteria of Chisolm and Mason9).
A detailed medical history of these 15 patients was obtained from their referring physicians, who also gave written permission for their patients to be studied.
Sera from a further 17 patients with Sjogren's syndrome, who had already been diagnosed in the rheumatology department at University College Hospital, were also studied. All of these patients also met the above criteria. All were women and their mean age was 64± (SD) 9-7 years. Twelve also had rheumatoid arthritis, one with renal tubular acidosis, one with fibrosing alveolitis, and one with hypothyroidism; one had systemic sclerosis; two had polyarthralgia of uncertain cause;
